medigraphic.com

2017, Number 2

<< Back Next >>

Rev Mex Anest 2017; 40 (2)

Understanding the concept of opioid-refractory pain

Carrillo-Torres O, Medina-Hernández PJ

Language: Spanish
References: 42
Page: 90-102
PDF size: 244.66 Kb.


ABSTRACT

In recent years the population in palliative care has been exponentially increasing with the advancement in medical therapy, the lifetime of the patients has been extended, so that the same definition have chosen not to take into account the time of probable death from the underlying disease. This change has meant that patients have no common symptomatology previously as pain refractory to opioids. Currently there are reports of up to 15% of refractory pain in cancer context, pointing to his own units of chronic and acute pain treatment techniques. Unable to count on the most important for the management of moderate to severe pain arsenal, they have investigated other types of drugs that work in this entity. Among the most studied are dexmedetomidine, ketamine, lidocaine and methadone; these have proved effective in varying amounts. The aim of the study is to review the indications and the effectiveness of various treatments in the context of refractory pain.


REFERENCES

  1. Estrategia Nacional de Cuidados Paliativos del Sistema Nacional de Salud. Ministerio de Sanidad y Consumo. España, 2007.

  2. Shekhar S, Rajagopal M, Gayatri P, Charu S, Altaf GH. A phase II Pilot study to evaluate use of intraveous lidocaine for opioid refractarory pain in cancer patients. J Pain Symptom Manage. 2009;3:85-93.

  3. Merskey H. Pain terms: a list with definitions and notes on usage. Recommended by the Subcommittee on Taxonomy. Pain. 1979;6:249-252.

  4. Covarrubias-Gómez A, Guevara-López U. Manejo del dolor crónico en la paciente obstétrica. En: Carrillo-Esper R (ed.). Clínicas Mexicanas de Anestesiología. Volumen 1. México. 2006: 39-51.

  5. Merskey H (ed). Classification of chronic pain; descriptions of chronic pain syndromes and definitions of pain terms. Monograph for the sub-commitee on taxonomy, International Association for the study of pain. Pain. 3rd ed. Amsterdam: Elservier science; 1986.

  6. Loeser JD. Medical evaluation of the patient with pain. En: Loeser JD (ed.). Bonica’s management of pain. 3rd ed. EUA. 2001. pp. 267-278.

  7. Pernia A, Torres LM. Tratamiento del dolor oncológico terminal intenso. Process management in pain treatment. 2008.

  8. Bruera E, Kim HN. Cancer pain. JAMA. 2003;290:2476-2479.

  9. World Health Organization. Cancer Pain Relief. Geneva: WHO Office of Publications; 1986.

  10. National Comprehensive Cancer Network. Clinic Practice Guidelines in Oncology v.1.2004. Cancer Pain. Geneva: WHO Office of Publications; 2004.

  11. World Health Organization. National Cancer Control Programmes. Political and Managerial Guidelines.Executive Summary; 2002.

  12. Cleary JF. Cancer pain management. Cancer Control. 2000;7:120-131.

  13. Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR. Symptom prevalence and control during cancer patients last days of life. J Palliat Care. 1990;6:7-11.

  14. Teng J. Cancer pain and neurolysis. Semin Anesth. 2003;22:175-185.

  15. Torres LM. De la escalera al ascensor. Rev Soc Esp Dolor. 2002;9:289-290.

  16. Plancarte SR, Mille LJ, Mayer RF. Manejo del dolor en cáncer. Cir Ciruj. 2002;70:356-368.

  17. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2002;20:348-352.

  18. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10:13-35.

  19. Fukshansky M, Are M, Burton AW. The role of opioids in cancer pain management. Pain Pract. 2005;5:43-53.

  20. Heavner J, Hill S, Hassenbusch S. Opioid use to treat cancer pain and chronic pain: the challenges transcend borders. Pain Prac. 2005;5:1-10.

  21. González-Barboteo J, Trelis-Navarro J, Tuca-Rodríguez A, Gomez-Batiste X. Opioid rotation: a therapeutic choice in the management of refractory cancer pain. 2010;135:617-622.

  22. Nazarian A, Christianson CA, Hua XY, Yaksh TL. Dexmedetomidine and ST-91 analgesia in the formalin model is mediated by 2A-adrenoceptors. Br J Pharmacol. 2008;155:1117-1126.

  23. Grosu I, Lavand’homme P. Use of dexmedetomidine for pain control. F 1000 Med Rep. 2010;2:90.

  24. Vargas-Rumoroso K, Salas-Herrera I. Ketamina en el manejo del dolor refractario por cáncer. Acta Med Costarric. 2006;48:61-63.

  25. Carrillo-Torres O y cols. Dexmedetomidina en la medicina actual. Rev Mex Anest. 2014;37:27-34.

  26. Eisenach J. Preemptive hyperalgesia, not analgesia? Anesthesiology. 2000;92:308-309.

  27. Klimscha W, Chiari A, Krafft P, Plattner O, Taslimi R, Mayer N, et al. Hemodynamic and analgesic effects of clonidine added repetitively to continuous epidural and spinal blocks. Anesth Analg. 1995;80:322-327.

  28. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Epidural epinephrine and clonidine: Segmental analgesia and effects on different pain modalities. Anesthesiology. 1997;87:785-794.

  29. Wienbroun A, Ben-Abraham R. Dextromethorphan and dexmedetomidine, new agents for the control of perioperative pain. Eur J Surg. 2001;167:563-569.

  30. Hayashid K, Eisenach JC. Spinal-2 adrenoreceptor-mediated analgesia in neurophatic pain reflex brain-derived nerve growth factor and changes in spinal cholinergic neuronal function. Anesthesiology. 2010;113:406-412.

  31. Puke MJ, Wiesenfeld-Hallin Z. The differential effects of morphine and the a-adrenoceptor agonists clonidine and dexmedetomide on the prevention and treatment of experimental neurophatic pain. Anesth Analg. 1993;77:104-109.

  32. Roberts SB, Wozencraft CP, Coyne PJ, Smith TJ. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. J Palliat Med. 2011;14:371-373.

  33. Prommer E. Dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care. 2011;28:276-283.

  34. Coyne PJ, Wozencraft CP, Roberts SB, Barton B, Smith TJ. Dexmedetomidine: Exploring its potential role and dosing guideline for its use in intractable pain in the palliative care setting. J Pain Palliat Care Pharmacother. 2010;24:384-386.

  35. Challapalli V, Tremont-Lukats IW, Mcnicol ED, Lau J, Carr DB. Administración sistemática de agentes anestésicos locales para aliviar el dolor neuropático. Oxford. 2006. En la biblioteca Cochrane plus número 1 [http://www.update-sofware.com]

  36. Whizar-Lugo V, Ochoa G. Conceptos actuales en dolor por cáncer. Anestesia en México. 2005;17:53-69.

  37. Bach FW, Jensen TS, Kastrup J, Strigsby B, Dejgård A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain. 1990;40:29-34.

  38. Kvarnström A, Karlsten R, Quiding H, Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand. 2004;48:498-506.

  39. Ellemann K, Sjögren P, Banning AM, Jensen TS, Smith T, Geertsen P. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989;5:291-294.

  40. Carrillo-Torres O, Gallegos-Allier MM, Jimenez-Olvera. Comparación entre dexmedetomidina en infusión intravenosa vs. lidocaína en infusión intravenosa para el control de dolor refractario a tratamiento opioide en pacientes de cuidados paliativos. Rev Soc Esp Dolor. 2015;22:7-13.

  41. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998;16:3216-3221.

  42. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med. 2002;5:127-138.




2020     |     www.medigraphic.com